Mesoblast’s Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in the U.S.
Mesoblast’s Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
Where Today's News Shapes Tomorrow
